Clinical trials: Margin, Tumor-Free
- Condition Margin, Tumor-Free
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema
Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.
A Phase 2b study investigating the efficacy of zabalafin in people with mild to moderate atopic dermatitis (eczema).
- Conditions
- Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema, Atopic Dermatitis, Atopic Dermatitis (AD)
- Trial name
- CLEAR-AD1 (NCT06855745)
- Testing
- zabalafin
- Where
- 12 sites in Australia
- Volunteers
- 72 people
- Sponsor
- Alphyn Biologics
Contact Lens Care
AOSEPT (CLEAR CARE) PLUS Study
The purpose of this post-market clinical follow-up (PMCF) study is to evaluate the long-term safety and performance of 2 commercially available contact lens cleaning and disinfecting systems in a pediatric population.
- Trial name
- NCT06588400
- Testing
- AOSEPT Plus and AOCup lens case, AOSEPT Plus with HydraGlyde and AOCup lens case, Habitual contact lenses
- Where
- United States
- Sponsor
- Alcon Research
Moderate to Severe Plaque-type Psoriasis
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis.
- Trial name
- GAIN (NCT02474069)
- Testing
- Secukinumab
- Where
- 89 sites in Germany
- Volunteers
- 772 people
- Sponsor
- Novartis Pharmaceuticals
Ewing Sarcoma, Myxoid Liposarcoma
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
This rollover protocol allows continued access to seclidemstat (SP-2577) for patients who are still receiving clinical benefit on completed or closed Salarius sponsored studies.
- Conditions
- Ewing Sarcoma, Myxoid Liposarcoma, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma
- Trial name
- NCT05266196
- Testing
- Seclidemstat
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Salarius Pharmaceuticals, LLC
Refractive Error, Glaucoma
A Post-market Clinical Study to Collect Safety and Performance Data on Johnson & Johnson Surgical Vision Products
Retrospective collection of data from medical records, multicenter, post-market clinical follow-up study.
- Conditions
- Refractive Error, Glaucoma, Cataracts, Clear Lens Exchange
- Trial name
- NCT05394324
- Testing
- Intervention
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 1,674 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Pediculoses, Head Lice
Neem Lotion With Combing for Lice
This was a Phase IIa randomised, assessor blinded, parallel group study in which half the participants were treated with Nice 'n Clear neem-based conditioning lotion plus combing with a head louse detection and removal comb and…
- Trial name
- NCT02974088
- Testing
- Neem-based lotion plus louse comb, Neem-based lotion plus grooming comb
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Medical Entomology Centre
Malocclusion
The Use of Clear Aligners With Movement Enhancement Techniques
The purpose of this study is to use clear aligners to measure tooth movement and length of treatment.
- Trial name
- NCT02087163
- Testing
- Movement Enhancement Technique, Clear Aligner
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Align Technology, Inc.
Myopia, Refractive Error
A Comparison of Two Color Contact Lenses in Habitual Clear Contact Lens Wearers
The purpose of this study was to evaluate overall satisfaction with AIR OPTIX® COLORS as compared to FRESHLOOK® COLORBLENDS contact lenses.
- Trial name
- NCT01782482
- Testing
- Lotrafilcon B contact lens with color, Phemfilcon A contact lens with color
- Volunteers
- 574 people
- Sponsor
- Alcon Research
Chronic Hepatitis D Infection
A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)
This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.
- Trial name
- NCT07499544
- Testing
- Libevitug 20 mg/kg, Libevitug 10 mg/kg, Delayed treatment with libevitug
- Where
- 7 sites in United States, China and 1 more
- Volunteers
- 160 people
- Sponsor
- Huahui Health
Malocclusion
Class II Correction Study Using the Invisalign System
To demonstrate that growing teenagers which present up to full cusp Class II malocclusions can be treated using the Invisalign System.
- Trial name
- NCT02376829
- Testing
- Invisalign System
- Where
- 10 sites in United States, Canada
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Align Technology, Inc.
Malocclusion
Evaluation of Clear Aligner Trays to Straighten Teeth
The objective of this study is to evaluate the efficacy of Clear Aligners to correct tooth malocclusions with the use of attachments and/or buttons, as determined by the amount of teeth movement and overall achievement goals of…
- Trial name
- NCT03141788
- Testing
- Clear Aligner
- Where
- 9 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Solventum Orthodontics Corporation
Sarcoma, Clear Cell
To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
The goal of this trial in Phase I is to determine the maximally tolerated dose (MTD) of hydroxychloroquine in combination with devimistat in patients with relapsed or refractory Clear Cell Sarcomas of the Soft Tissue and to…
- Trial name
- NCT04593758
- Testing
- CPI-613 + Hydroxychloroquine
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Cornerstone Pharmaceuticals
Clear Cell Sarcoma
QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma
This is a phase 2 study that will assess the efficacy of AMG 337 in subjects with advanced or metastatic clear cell sarcoma that contains the EWSR1-ATF1 gene fusion.
- Trial name
- NCT03132155
- Testing
- AMG 337
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- NantPharma, LLC
Hearing Loss
CLEAR Clinical Study
Acute in-booth assessment of a new noise reduction algorithm with cochlear implant recipients.
- Trial name
- NCT03126825
- Testing
- CP910/CP920 with noise reduction on, CP910/CP920
- Where
- 2 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Cochlear
Hypercholesterolemia
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Multiple-dose study to measure pharmacokinetics, pharmacodynamics and safety of bempedoic acid in pediatric participants 6 to 17 years of age with HeFH.
- Trial name
- CLEAR Path 1 (NCT05694260)
- Testing
- Bempedoic acid
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 31 people
- Sponsor
- Esperion Therapeutics, Inc.
Uveal Melanoma
5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes
Uveal Melanoma is a rare cancer with approximately 3,000 cases diagnosed in the US every year. Nearly half of these experience spread of their cancer outside the eye.
- Trial name
- CLEAR (NCT02376920)
- Volunteers
- 93 people
- Sponsor
- Castle Biosciences Incorporated
Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS)
Phase 2 Study in Patients With MiT Tumors
This is a multi-center, single arm intended to evaluate the anti-tumor effect of ARQ 197 in patients with microphthalmia transcription factor associated (MiT) tumors.
- Conditions
- Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS), Clear Cell Sarcoma (CCS)
- Trial name
- NCT00557609
- Testing
- ARQ 197
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 47 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Solid Tumor, Clear Cell Renal Cell Carcinoma
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with…
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT05199272
- Testing
- 23ME-00610
- Where
- 13 sites in United States, Canada
- Volunteers
- 141 people
- Sponsor
- 23andMe, Inc.
Myopia
A Comparison of Two Color Contact Lenses in Habitual Clear Contact Lens Wearers
The purpose of this study is to evaluate the comfort of color contact lenses in a population of clear contact lens wearers who have an interest in wearing color contact lenses.
- Trial name
- NCT02175199
- Testing
- Lotrafilcon B contact lenses with color printing, Phemfilcon A contact lenses with color printing
- Volunteers
- 151 people
- Sponsor
- Alcon Research